제테마
Financials
Valuation Metrics
제테마's Market Cap is ₩2595B. At end of 2025 it was ₩2282B. Ranked #728 of 2,421 in KR market (top 30%), #316 of 1,640 on KOSDAQ (top 19%), #78 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 259.52B KRW | KR#728/2,421 Sec#78/231 |
| Revenue | 76.58B KRW | KR#1,568/2,421 Sec#100/231 |
| Net Income | -1.93B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 243.65B KRW | KR#1,157/2,421 Sec#80/231 |
| Net Assets | 80.71B KRW | KR#1,582/2,421 Sec#128/231 |
| Employees | 243 | KR#946/2,421 Sec#81/231 |
| Value | ||
| P/B | 3.22x | KR#2,125/2,421 Sec#171/231 |
| P/S | 3.39x | KR#2,034/2,421 Sec#127/231 |
| EV/EBITDA | 92.51x | KR#1,479/2,421 Sec#97/231 |
| FCF Yield | 2.08% | KR#1,046/2,421 Sec#69/231 |
| Profitability | ||
| ROE | -2.39% | KR#1,708/2,421 Sec#120/231 |
| ROA | -0.79% | KR#1,649/2,421 Sec#113/231 |
| Op. Margin | 5.00% | KR#962/2,421 Sec#72/231 |
| Revenue Growth | 8.79% | KR#965/2,421 Sec#94/231 |
| Financial Health | ||
| Debt Ratio | 201.88% | KR#2,110/2,421 Sec#219/231 |
| Total Debt | 132.44B KRW | KR#642/2,421 Sec#36/231 |
| FCF | 5.39B KRW | KR#884/2,421 Sec#60/231 |
| Cash | 37.55B KRW | KR#883/2,421 Sec#57/231 |
| Current Ratio | 0.79x | KR#1,951/2,421 Sec#190/231 |
| Net Debt/EBITDA | 24.77x | KR#1,404/2,421 Sec#100/231 |
| Performance | ||
| 1Y Return | 8.92% | KR#582/2,421 Sec#35/231 |
| 1M Return | 71.85% | KR#30/2,421 Sec#3/231 |
| From 52W High | -38.30% | KR#848/2,421 Sec#57/231 |
| 1Y MDD | -62.81% | KR#1,638/2,421 Sec#132/231 |
| Trading | ||
| Volume | 158,440 shares | KR#565/2,421 Sec#39/231 |
| Trading Value | 1.09B KRW | KR#696/2,421 Sec#71/231 |
| Foreign Own. | 2.84% | KR#1,339/2,421 Sec#121/231 |
| Per Share | ||
| EPS | -52 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,165 KRW | KR#2,032/2,421 Sec#166/231 |
Company Info
Jetema originated in 2009 as a bio research company focused on chitosan-applied DDS development. Through a 2014 merger and the 2015 completion of a filler-exclusive factory, the company entered the medical aesthetic market, successfully venturing into the toxin market in 2024. Jetema actively researches and develops hyaluronic acid fillers, botulinum toxin-based pharmaceuticals, sutures, and lifting threads. The company is expanding its global presence, securing license-out agreements with Brazil (2020) and China (2022), and pursuing export contracts with Thailand and market entry into the US in 2024. Jetema is headquartered in Wonju City, Gangwon-do.